Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of galantamine in subjects with mild cognitive impairment.
Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS; GAL-INT-11/18 Study Group. Winblad B, et al. Among authors: brashear hr. Neurology. 2008 May 27;70(22):2024-35. doi: 10.1212/01.wnl.0000303815.69777.26. Epub 2008 Mar 5. Neurology. 2008. PMID: 18322263 Clinical Trial.
Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group. Auchus AP, et al. Among authors: brashear hr. Neurology. 2007 Jul 31;69(5):448-58. doi: 10.1212/01.wnl.0000266625.31615.f6. Neurology. 2007. PMID: 17664404 Clinical Trial.
Analyses of mortality risk in patients with dementia treated with galantamine.
Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin JA, Battisti WP, Kavanagh S. Feldman HH, et al. Among authors: brashear hr. Acta Neurol Scand. 2009 Jan;119(1):22-31. doi: 10.1111/j.1600-0404.2008.01047.x. Epub 2008 Jun 1. Acta Neurol Scand. 2009. PMID: 18518863
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA. Carrillo MC, et al. Among authors: brashear hr. Alzheimers Dement. 2013 Mar;9(2):123-131.e1. doi: 10.1016/j.jalz.2012.12.004. Epub 2013 Feb 12. Alzheimers Dement. 2013. PMID: 23411394 Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: brashear hr. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.
Prins ND, van der Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, Barkhof F, Scheltens P. Prins ND, et al. Among authors: brashear hr. Alzheimers Res Ther. 2014 Jul 21;6(4):47. doi: 10.1186/alzrt275. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25478019 Free PMC article.
101 results